GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (NAS:ABCL) » Definitions » Cash Flow from Investing

AbCellera Biologics (AbCellera Biologics) Cash Flow from Investing : $-41.59 Mil (TTM As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is AbCellera Biologics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, AbCellera Biologics spent $24.14 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $5.91 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $253.76 Mil on purchasing investments. It gained $306.55 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it received $7.17 Mil from other investing activities. In all, AbCellera Biologics gained $29.91 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


AbCellera Biologics Cash Flow from Investing Historical Data

The historical data trend for AbCellera Biologics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Cash Flow from Investing Chart

AbCellera Biologics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial -5.78 -119.78 -332.25 -352.63 -221.11

AbCellera Biologics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -149.61 -34.39 -12.79 -24.32 29.91

AbCellera Biologics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

AbCellera Biologics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

AbCellera Biologics's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-41.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AbCellera Biologics  (NAS:ABCL) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

AbCellera Biologics's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-24.14 Mil. It means AbCellera Biologics spent $24.14 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

AbCellera Biologics's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means AbCellera Biologics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

AbCellera Biologics's purchase of business for the three months ended in Mar. 2024 was $-5.91 Mil. It means AbCellera Biologics spent $5.91 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

AbCellera Biologics's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means AbCellera Biologics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

AbCellera Biologics's purchase of investment for the three months ended in Mar. 2024 was $-253.76 Mil. It means AbCellera Biologics spent {stock_data.stock.currency_symbol}}253.76 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

AbCellera Biologics's sale of investment for the three months ended in Mar. 2024 was $306.55 Mil. It means AbCellera Biologics gained $306.55 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

AbCellera Biologics's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means AbCellera Biologics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

AbCellera Biologics's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means AbCellera Biologics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

AbCellera Biologics's cash from other investing activities for the three months ended in Mar. 2024 was $7.17 Mil. It means AbCellera Biologics received $7.17 Mil from other investing activities.


AbCellera Biologics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


AbCellera Biologics (AbCellera Biologics) Business Description

Traded in Other Exchanges
Address
2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Executives
John S. Montalbano director C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Michael R Hayden director C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Veronique Lecault director, officer: Chief Operating Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Thermopylae Holdings Ltd. 10 percent owner 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Booth officer: Chief Financial Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Andrew Lo director C/O ALPHASIMPLEX GROUP, LLC, ONE CAMBRIDGE CENTER, 9TH FLOOR, CAMBRIDGE MA 02142
John Hamer director, 10 percent owner PO BOX 14528, RESEARCH TRIANGLE PARK NC 27709-4528
Ester Falconer officer: Chief Technology Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Hansen Carl L. G. director, 10 percent owner, officer: Chief Executive Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Tryn Stimart officer: Chief Legal Officer C/O ABCELLERA BIOLOGICS INC., 2215 YUKON STREET, VANCOUVER A1 V5Y 0A1
Peter Thiel director 9200 SUNSET BOULEVARD, SUITE 1110, WEST HOLLYWOOD CA 90069
Dcvc Bio, L.p. 10 percent owner 317 UNIVERSITY AVENUE, SUITE 200, PALO ALTO CA 94301
Dcvc Bio Gp, Llc 10 percent owner 270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Zachary Bogue 10 percent owner 270 UNIVERSITY AVENUE, PALO ALTO CA 94301
Matthew Ocko 10 percent owner 270 UNIVERSITY AVENUE, PALO ALTO CA 94301